Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

When an undercover agent offered $3,500 for two 100 milligram vials of the drug, Kumar said, “At this price, we can’t deliver real or genuine Keytruda.” “Product will look like same but it ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Even if you’re not a professional photographer, the right product photography setup can improve your website’s credibility and attract more customers. Your existing customers already know what ...

and follow positive recommendations from the Committee for Medicinal Products for Human Use received in September 2024. In NRG-GY018/KEYNOTE-868, KEYTRUDA in combination with carboplatin and ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck (MRK) is set to announce Q3 earnings on October 31st. Analysts expect a profit of $1.57 per share on revenue of $16.51B ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab ... recommendations from the Committee for Medicinal Products for Human Use received in September 2024.